Even with sluggish patient volume, reimbursement pushbacks, and the
medical device tax, it hasn't been a bad year for the med-tech sector,
and there aren't all that many bargains left. Abbott Labs (NYSE:
ABT) is certainly not a med-tech pure play (more than 50% of revenue
comes from non-device businesses), but it gets grouped into the sector
all the same, and this does appear to be one of the few remaining
bargains. While Abbott still has work to do on its margins, and more
growth in the device business would be very welcome, these shares look
like a relative bargain in an increasingly expensive market.
Please continue here:
http://www.fool.com/investing/general/2013/10/16/abbott-a-little-light-on-growth-but-margin-improve.aspx
No comments:
Post a Comment